← Browse by Condition
Medical Condition
heterozygous familial hypercholesterolemia hefh
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 3
NCT07058077 Phase 2, Phase 3
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Enrollment
153 pts
Location
United States, Austr...
Sponsor
Merck Sharp & Dohme LLC
NCT07470723
Recruiting
The ORIGIN-FH Study
Enrollment
70 pts
Location
United States
Sponsor
University of Wisconsin, Madis...